During the corresponding time, Aurinia Pharmaceuticals Inc recorded a revenue increase by 18.87 % year on year, sequentially revenue grew by 7.1 %. While revenue at the Aurinia Pharmaceuticals Inc 's corporate clients
Aurinia Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company addresses regulatory requirements and compliance related to marketing pharmaceutical products, including LUPKYNIS, in the United States and foreign countries. This involves obtaining approvals from the U.S. Food and Drug Administration (FDA) and foreign regulatory authorities, as well as adhering to laws such as the Health Insurance Portability and Accountability Act (HIPAA) and the Physician Payment Sunshine Act.
The Promising Safety and Efficacy Profile of LUPKYNIS for Lupus Nephritis Revealed at EULAR Congress 2024Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a leading biopharmaceutical company, recently showcased compelling new data on the safety and effectiveness of its drug LUPKYNIS (voclosporin) for the treatment of lupus nephritis. The company presented the findings during an oral presentation at the prestigious European Alliance of Associations for Rheumatology (EULAR) Congress 2024, held in Vienna, Austria from June 12 to 15.The presented data further corroborates the positive results obtained from the AURORA Clinical Program, affirming LUPKYNIS as a robust therapeutic option for adult patients suffering fro...
Aurinia Pharmaceuticals Inc. recently presented the results of an updated cost-effectiveness analysis of LUPKYNIS (voclosporin), a second-generation calcineurin inhibitor (CNI), during the National Kidney Foundation (NKF) Spring Clinical Meeting 2024 in Long Beach, CA. The outcome of the analysis traditionally holds significant implications for lupus nephritis patients and their healthcare providers owing to the potential long-term cost savings.Lupus nephritis, a serious health condition, is associated with systemic lupus erythematosus and can lead to kidney damage, kidney failure, and other complications if left untreated. Bearing this in mind, the need for effective, affordable treatments are of paramount ...
In honor of Lupus Awareness Month, Aurinia Pharmaceuticals is intensifying its efforts to promote awareness and education about the debilitating impact of Lupus Nephritis (LN). Through various initiatives and a comprehensive disease state education campaign for rheumatologists, Aurinia aims to shed light on the severity of LN and the urgent need for frequent screening and effective management.The Significance of Lupus Nephritis:Lupus Nephritis is a severe and potentially life-threatening complication of systemic lupus erythematosus (SLE), an autoimmune disease that primarily affects women of childbearing age. LN primarily targets the kidneys, causing inflammation and damage to the delicate filters responsibl...
Aurinia Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company addresses regulatory requirements and compliance related to marketing pharmaceutical products, including LUPKYNIS, in the United States and foreign countries. This involves obtaining approvals from the U.S. Food and Drug Administration (FDA) and foreign regulatory authorities, as well as adhering to laws such as the Health Insurance Portability and Accountability Act (HIPAA) and the Physician Payment Sunshine Act.
Sources:
Aurinia Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Aurinia Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Aurinia Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
183.82 %